Healthcare / BiotechnologyTokyo
$241.00
-5.00 (-2.03%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-141.1M · quality 33.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.3B
P/E
37.0x
↑EV/EBITDA
N/A
•ROE
-3.5%
↓Gross Margin
49.7%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-19.7%
FCF CAGR
-37.1%
FCF margin
10.7%
FCF / Net income
-2.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.85B · net income $-210.7M · FCF $520.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.85B | $4.85B | $5.16B | $8.08B | $9.35B |
| Net Income | $-210.7M | $-210.7M | $-662.2M | $451.8M | $809.7M |
| EBITDA | $-119.1M | $-119.1M | $-583.2M | $750.5M | $1.23B |
| EPS | -8.05 | -8.05 | -25.32 | 17.27 | 30.95 |
| Gross Margin | 49.7% | 49.7% | 48.1% | 46.0% | 45.6% |
| Operating Margin | -2.8% | -2.8% | -11.8% | 9.0% | 12.9% |
| Net Margin | -4.3% | -4.3% | -12.8% | 5.6% | 8.7% |
| Balance Sheet | |||||
| Current Ratio | 9.44 | 9.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $520.5M | $520.5M | $-895.4M | $-141.1M | $2.09B |
| Returns | |||||
| ROE | -3.5% | -3.5% | -10.6% | 6.5% | 12.2% |
| Valuation | |||||
| P/E | 37.02 | 37.02 | — | 16.68 | 10.79 |
| EV/EBITDA | — | — | — | 2.12 | 2.21 |
| P/B | 1.05 | 1.05 | 0.71 | 1.08 | 1.31 |
| Growth & Yield | |||||
| Revenue Growth | -6.0% | -6.0% | -36.2% | -13.6% | — |
| EPS Growth | 68.2% | 68.2% | -246.6% | -44.2% | — |
| Dividend Yield | 4.2% | 4.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+60.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-25.32 → -8.05
Residual
+56.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.